NovAccess Global

NovAccess Global, Inc. is a biopharmaceutical company, which engages in the provision of diagnostics, therapeutics in cancer, and neurological diseases and the development of immunotherapies to treat brain tumor patients. The company is headquartered in Chagrin Falls, Ohio and currently employs 1 full-time employees. The company went IPO on 2002-05-01. The firm develops immunotherapies to treat brain tumor patients in the United States. The company specializes in research related to utilizing a patient’s own immune system to attack the cancer. Its dendritic cell-based immunotherapy utilizes a combination of Toll-like receptor adjuvants for an enhanced antitumor response. The therapy is designed to utilize the patient’s tumor antigens and immune cells, dendritic cells, in combination with TLR adjuvants to initiate an efficient antitumor immune response. This process includes obtaining the patients' tumor cells after surgery, and precursors cells that are matured into dendritic cells from peripheral blood. Its TLR-AD1 platform technology is a vaccine immunotherapy for the treatment of aggressive brain cancers, including glioblastoma and other high-grade gliomas. TLR-AD1 technology has a scope of use and is embodied in various different product lines for different clinical situations.